title: Clinical experience with thrombolytic agents.
abstract: It is now possible through the administration of thrombolytic therapy to dissolve an obstructive thrombus in the coronary artery. On the basis of the pathophysiology of acute MI, this should translate into interruption of the ischemic process and benefit to the patient. Clinical trials with t-PA and SK have supported this concept by demonstrating preservation of LVF, reduction in congestive heart failure, and reduction in mortality. All clinical data point to the importance of early intervention and treatment in attaining maximal patient benefit. Studies have shown the safety and feasibility of early treatment in the emergency setting. In the era of thrombolytic therapy, there is an opportunity for the emergency physician and nurse to play a significant role in the treatment of the patient with acute MI. Prompt intervention with thrombolytic therapy in the emergency department will offer the patient the greatest opportunity for benefit.
authors.forename: E
authors.initials: E
authors.lastname: Henderson
mesh_terms: D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012107:Research Design; D013300:Streptokinase / Q000627:therapeutic use; D013318:Stroke Volume / Q000187:drug effects; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator